INTRODUCTION Peripheral arterial di...

INTRODUCTION

Peripheral arterial disease (PAD) is a habitual manifestation of atherosclerosis, a systemic condition of plaque deposition in the arteries leading to narrowing of the arterial circulation in the lower extremities and adversely affecting health, walking and quality of life.1 PAD is a prevalent and chronic question of the elderly, with a prevalence estimated at 12% of the general population,2 increasing to 20% in the public over the age of 703 The primary symptom of PAD is intermittent claudication (IC),4 a cramping leg pain that come into one's heads with walking, causing the individual to stop walking and to quiet until the pain subsides. It is characterized by way of being highly reproducible, occurring with a consistent flat of walking from one day to the nearest disappearing after 2 to 3 minutes of cessation and recurring at a consistent even of exercise. Patients with PAD-IC report difficulties with walking quickly and for drawn out distances, resulting in limitations of ambulatory activities that can be significantly disabling.1

While the ankle-brachial index (ABI) is the gold standard for identifying the neighborhood or severity of PAD, there is a poor correlation between ABI severity and symptoms of intermittent claudication. In persons with PAD, less than 20% report symptoms of intermittent claudication.5 Rather than quantifying the severity of PAD with ABI, there is a ne to assess the functional limitations associated with IC in patients with the one and the other PAD and IC, especially when evaluating the general intents of therapy. The success of therapy is typically evaluated using clinical measures of disease, function, and quality of life. In the case of PAD and 1C baseline assessment of functional status can help direct therapy for each patient. Medical management of someones with PAD is directed at reducing cardiovascular risk factors and reducing the impact of claudication. Intervention that is specifically directed at improving function, as it is as that provided by rehabilitation providers requires a comprehensive assessment of the patient's performance and functional status. This article reviews guidelines for measurement of clinical and selfreport measures useful in measurement of physical function and quality of life (QOL) in race with PAD-IC. First, measures of intermittent claudication will be neared followed by a discussion of other physical performance measures, generic self-report measures of community based ability followed by dint of PAD-specific tools for functional flat and QOL. The measures are summarized in Table 1

MEASUREMENT OF INTERMITTENT CLAUDICATION OUTCOMES

In order to measure the clinical and functional rehabilitation results in people with PAD-IC, a comprehensive approach is commended Outcome measurements should include clinical measures of claudication severity and walking ability, as well as patient-centered assessment of physical function and quality of life.

MEASUREMENT OF CLAUDICATION SEVERITY

Presence of claudication

To improve reporting in cpidemiologic studies a questionnaire was designed to identify the prevalence of intermittent claudication.'1 Since that time, additional questionnaires were expanded and are typically used to assess the neighborhood of intermittent claudication. The Edinburgh Claudication Questionnaire demonstrates a sensitivity of 91% and specificity of 99% compared to diagnosis by the agency of a physician.7 The too] has upright repeatability with test-retest values at 78 with kappa correlation coefficients.

Treadmill testing

Treadmill testing is an objective measure of walking performance and thus is the measurement greatest in quantity frequently used in both research and clinical settings to measure change after a therapeutic intervention. The primary endpoint of treadmill testing is the peak walking time, also called absolute claudication distance. This measure indicates the absolute amount of time (or distance) a patient can walk onward the treadmill before claudication pain forces the individual to stop walking. A secondary cndpoint is pain exempt walking time (also called initial claudication distance) and indicates the time to attack of claudication pain. The variability in time to assault of claudication pain has been reported to be about 25% from touchstone to test." A drop of ankle systolic constraining force by more than 20% after exercise testing is considered abnormal.

The treadmill protocols advocated for use in the PAD population are different than those used to assess exercise performance in coronary artery disease (CAD). The typical exercise touchstone used in CAD rapidly increase the one and the other speed and grade to symptom limited maximum exercise capacity. Patients with PAD are many times limited in walking speed. The treadmill protocols used in PAD are either graded (where the spe is fixed at 2 or 3 mph and the grade increases with each stage) or constant load, where the two speed and grade are fixed.8,9

Clinical measures of physical performance

Physical performance measures are instruments that assess aspects of physical function in a quantifiable manner.10 These measures are useful in that they are responsive to change, they identify a range of limitations not identified through self-report, are responsive to change after interventions of that kind as exercise, and predict results such as need for nursing place of abode placement or utilization of services.10